Trastuzumab for the treatment of salivary duct carcinoma. - Wikidata - wikimedia - TriplyDB

Trastuzumab for the treatment of salivary duct carcinoma.

Trastuzumab for the treatment of salivary duct carcinoma.

http://www.wikidata.org/entity/Q36714388

about

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.Breast metastasis of salivary duct carcinoma in a patient: a case report.Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland Salivary Duct Carcinoma of the Parotid: Outcomes with a Contemporary Multidisciplinary Treatment Approach.Salivary gland malignancies - an update on current management for oral healthcare practitioners.A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases.Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.Outcomes and prognostic factors for surgery followed by modern radiation therapy in parotid gland carcinomas.Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.Submandibular gland cancer: Specific features and treatment considerations.Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.Somatic mutations in salivary duct carcinoma and potential therapeutic targets.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Primary salivary gland malignancies: a review of clinicopathological evolution, molecular mechanisms and management.Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment.Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab.Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas.Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses.Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis.

P2860

Q26781643-99D92838-355A-40F2-8A31-A76175D50B40 Q33645792-D393A3EC-B910-4711-9A5A-70748B424C73 Q34532980-976E61E8-9783-447B-9F39-2BD9B34E71F9 Q35230643-20D38F18-5B87-4307-8D29-F455F1B58254 Q36317852-FFD97FFE-6264-4E72-8BE8-8361E559678F Q36493317-E14E61AD-F62B-454D-BE67-1064F24AB78C Q36874710-77C25357-18E2-4E4D-AD75-89F37847988A Q36902899-BC6C728D-8EF9-4029-B1F2-A88DB0890F67 Q38776386-19568B40-E24D-4408-98CD-99EDFA8E0406 Q38822353-9F362560-D5A9-47C6-8052-E51899AD6C5B Q38841254-2AB750A3-CEB3-482D-B2F6-09DFAC2F6147 Q39831543-386F465B-DD6E-45B2-A04B-0A1D190B43E0 Q40693954-43B67A0F-1D89-42DC-93F3-4DFA5FF1DBE1 Q40783341-C953F9DD-8905-4FEC-AC7F-2BC792623131 Q41708696-68C3979E-894F-4B1D-82D0-AE26A87627E3 Q41906973-903F3FEA-094F-401B-84CA-5047BEDE88BA Q42233857-8C2A48D5-2F8C-41B9-BD10-C261324BE5C4 Q45987424-964C7EF7-F92D-4AD9-89C4-1F8A12B68DA5 Q45996599-8600C52F-A706-4B70-88B6-E59F8CC93CAD Q47133482-07F9E714-E3B7-4A2C-A04F-5D8F3D69A8B9 Q47259493-C0D52649-AC49-483E-B13D-5C58E722E945 Q47433338-6159263A-1404-4338-9C6D-D942B5D0B920 Q47859326-E5976563-B9EA-4662-9849-8E1C46B21C52 Q47923316-F61D47ED-8E68-40FB-A5D1-938E723AF35A Q48123633-392110FC-12F4-4041-AF0E-8A0A3027FE45 Q48236697-49CFEF31-FA94-48F2-9FE1-C9487F7B2035 Q48249374-C2175701-37C6-4DB4-B520-79E4EBC8FEBE Q48334085-15EE2C01-5399-42FF-BF77-68794F156CBB Q50675747-6FC8708C-94E6-4136-81F6-93EC8AD8C5A0 Q51127479-ADE9E7E5-6A30-415F-96EE-193B918834A2 Q51709905-8F0CED03-CB5C-4621-B404-D725A1B634D0 Q53769670-01155298-D1E0-4F98-99B5-C4AA4064B8BC Q54145280-8AECEE88-C1AB-4856-94F5-9A738F00FAF2 Q54226554-5687F839-0AB1-4A13-A33B-9340432D6C38 Q54997136-933E0C26-A4C0-49DA-B06E-6BFEBE76121C

P2860

Trastuzumab for the treatment of salivary duct carcinoma.

http://www.wikidata.org/entity/Q36714388

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Trastuzumab for the treatment of salivary duct carcinoma.

@ast

Trastuzumab for the treatment of salivary duct carcinoma.

@en

type

label

Trastuzumab for the treatment of salivary duct carcinoma.

@ast

Trastuzumab for the treatment of salivary duct carcinoma.

@en

prefLabel

Trastuzumab for the treatment of salivary duct carcinoma.

@ast

Trastuzumab for the treatment of salivary duct carcinoma.

@en

P1433

Q36714388-79FC1DAC-36F6-453C-96AB-656D6AE8743A

P1476

Q36714388-C91FCB67-84A8-41A7-B88A-5A8086AE1745

P2093

Q36714388-5A9907AE-ECCC-425F-B0B4-CFC54F749AEE

Q36714388-5D02150D-0D02-4664-BA92-68112ABDB181

Q36714388-6B5E8D4C-366F-48BC-89E5-86F66640C182

Q36714388-810E6673-0ECF-4EB0-B406-DC960CAEF0DA

Q36714388-C031A9F2-687B-45C7-9FF6-D76074B5A810

Q36714388-C74E0767-1789-40CA-986A-BC8DCC1EAF7B

Q36714388-D257D2DA-94ED-41AC-B499-141D4EC04252

Q36714388-D9521A3A-830C-4722-AFBF-EE68CD90BCAB

Q36714388-FCA8C46A-FF3E-479F-9C2E-84E76E54BEC5

P2860

Q36714388-05673A97-AD52-4C91-9CA6-894433B489A2

Q36714388-06756A78-377E-4FEF-B922-E82D50334073

Q36714388-1B7149EE-969B-48FC-8D94-94ADDAC7B4D6

Q36714388-1D9F8821-197A-43BC-92D1-73D2AA009E36

Q36714388-20A926BB-3C0E-48C6-B021-A0B8C6B22DD3

Q36714388-2DCEBCCB-5A29-4631-8144-9B5DAB6DEEDD

Q36714388-3EDC2DF3-2CCC-44EB-A701-8110928200CD

Q36714388-406888CE-00DE-47A4-947E-CB2A4007D5EB

Q36714388-44D1877F-85B5-4279-8BFA-8C0750044D7A

Q36714388-456CF19A-6A2D-4D60-9B1B-3C67001416C6

P304

Q36714388-028CE44A-5C07-4402-ABAE-56084F78CED6

P31

Q36714388-9458336D-F40F-46DA-B342-17CCEC9B4EF8

P356

Q36714388-3B9FAC87-DACB-4667-A1BC-49DA0C992B69

P433

Q36714388-7643FF2A-77D3-47F9-A344-44479C30F9E2

P478

Q36714388-3DE5F007-C845-41A2-9454-AD18DC4DB749

P577

Q36714388-6630544D-D7B7-42D9-B184-64985E055913

P698

Q36714388-2B3E18BD-E5FD-455C-B469-2CC4C1B8972B

P932

Q36714388-08BD2435-3156-4B80-945E-89EA0C2C80DF

P356

THEONCOLOGIST.2012-0369

P1433

P1476

Trastuzumab for the treatment of salivary duct carcinoma.

@en

P2093

Aditya V Shreenivas

http://www.w3.org/2001/XMLSchema#string

Deborah A Dillon

http://www.w3.org/2001/XMLSchema#string

Jeffrey F Krane

http://www.w3.org/2001/XMLSchema#string

Jochen H Lorch

http://www.w3.org/2001/XMLSchema#string

Maria Fonfria

http://www.w3.org/2001/XMLSchema#string

Marshall R Posner

http://www.w3.org/2001/XMLSchema#string

Robert I Haddad

http://www.w3.org/2001/XMLSchema#string

Roy B Tishler

http://www.w3.org/2001/XMLSchema#string

Sewanti A Limaye

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Adjuvant trastuzumab in HER2-positive breast cancer.

Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.

Systemic therapy in the palliative management of advanced salivary gland cancers.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

P304

294-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0369

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23429737

http://www.w3.org/2001/XMLSchema#string

P932

3607526

http://www.w3.org/2001/XMLSchema#string